Category Archives: HIV care & treatment

CROI 2016: Switching to regimen with new form of tenofovir (TAF) improves kidney and bone health markers

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, 96-week results were presented from a phase 3 study that switched individuals from a regimen with the older version of tenofovir (tenofovir disoproxil fumarate, TDF) to a newer version (tenofovir alafenamide, TAF) to compare…Read More

CROI 2016: Early results show doravirine regimen as effective as efavirenz regimen

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, early 48-week results showed that the experimental NNRTI doravirine suppressed HIV levels as well as efavirenz (Sustiva) but with lower rates of side effects. No NNRTIs are currently listed as a “recommended” starting regimen…Read More

CROI 2016: New attachment inhibitor showing promise for treatment experienced patients

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, 96-week results were reported on from a Phase II study of BMS-663068 — a new class of drugs called attachment inhibitors. This type of drug works by attaching itself onto HIV’s receptor called gp120,…Read More

CROI 2016: Maintenance regimen of injected cabotegravir + rilpivirine advances through study

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, early results from the LATTE-2 study were presented on a maintenance regimen of cabotegravir + rilpivirine given by injection every 4 or 8 weeks. Cabotegravir is an experimental integrase inhibitor while the oral version…Read More

CROI 2016: Promising results for new, simpler dosing of raltegravir (Isentress)

croi2016sm

Although not presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, a press release was released near the start of CROI about a phase 3 study of the integrase inhibitor, raltegravir (Isentress). The study, called ONCEMRK, compared a new once-a-day dosing of…Read More

CROI 2016: Current HPV vaccine does not prevent anal cancer in people with HIV

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, discouraging news was reported on the HPV (human papilloma virus) vaccine Gardisil, revealing that it failed to reduce the persistence of HPV strains in anal and oral cells. This indicates that it won’t protect…Read More

2016 Presidential HIV/AIDS Questionnaire Results

Logo AIDS United sm

Go to the AIDS United page for the 2016 Presidential HIV/AIDS Questionnaire Results. According to the Centers for Disease Control and Prevention (CDC), 1.2 million people live with HIV in the United States and approximately 40,000 people are newly diagnosed annually. Although HIV was once considered a life-threatening illness,…Read More